---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-005333"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:12:32.061821+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q4 2022 net revenue $28.4M (+21% YoY); FY net revenue $134.0M (+194% YoY); net loss $0.18/share

## Summary
- Q4 2022 net product revenue $28.3M; FY 2022 net product revenue $103.5M.
- Net loss Q4 $26.0M ($0.18/share); FY net loss $108.2M ($0.76/share).
- Cash, equivalents and investments $389.4M at Dec 31, 2022.
- FY 2023 net product revenue guidance reiterated at $120-140M.
- Approx. 1,525 patients on LUPKYNIS therapy at year-end; 274 PSFs secured through Feb 24, 2023.

## SEC filing metadata
- accession: 0001628280-23-005333
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828023005333/0001628280-23-005333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828023005333/auph-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-005333
- JSON: https://secwatch.observer/filing/0001628280-23-005333.json
- Plain text: https://secwatch.observer/filing/0001628280-23-005333.txt

## Key facts
- Earnings Releases
  Aurinia Pharmaceuticals Inc. reported the quarter and year ended December 31, 2022 results: revenue $28.4 million. Guidance reaffirmed.
  - Period: the quarter and year ended December 31, 2022
  - Revenue: $28.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: filing. --- EX-99.1 (EX-99.1 PRESS RELEASE) --- PRESS RELEASE Document Exhibit 99.1 AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND COMPANY UPDATES $28.4 million in total net revenue for the fourth quarter 2022, a 21% increase over fourth quarter 2021 and $134.0 million for full year 2022, a 194% increase over 2021 Cash, cash equivalents,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000162828023005333/0001628280-23-005333-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.